1. e a b c d unstimulated +fMLP T308P-Akt S473P-Akt Akt (min)
+ fMLP (100 nM)
PH-Akt-GFP
Anti-PIP3 antibody
Figure 1a-e,
supplement

2. f
(min)
0.5 1
1.5 2 4
+ fMLP (100 nM)
Figure 1f,
supplement

3. a b DiD Overlay PH-Akt-GFP Ratio (PH-Akt-GFP/DiD)
Fig. 2a-b, supplement

4. c
Fig. 2c, supplement

5. a
HL-60
+ 50 nM wort
Figure 3a, supp

6. b d c + 200 nM wort T308P-Akt S473P-Akt Akt HL-60 + 50 mM LY
120
100 80
Relative level of
T308P-Akt (%) 60
+ 200 nM wort 40 c 20
120
T308P-Akt
100 80
S473P-Akt
Relative level of
S473P-Akt (%) 60 40
Akt 20
HL-60 1 2 3 4 5 6 7
+ 50 mM LY
HL-60 +fMLP
+ 20 nM wort
+ 50 nM wort
+ 200 mM LY
+ 400 mM LY
HL-60
+ 200 nM wort
+ 50 mM LY
+ 20 nM wort
+ 50 nM wort
+ 200 mM LY
+ 400 mM LY
+ 200 nM wort
Figure 3b-d, supplement

7. a b c HL-60 + wort 2 min 6 min 10 min Paths HL-60 + wort HL-60 HL-60
+ fMLP
150
HL-60
100 50 3 1 2 4
HL-60
HL-60
+ wort
+ 50 nM wort
+ 200 nM wort
Figure 4, supplement

8. a b c Cell Number Log [fMLP] (nM) PLB-985 + 30 nM wortmannin
4000
Cell Number
2000
0.1 1 10
100
Human blood neutrophils
Log [fMLP] (nM) c
PLB-985
+ 200 mM LY
+ 30 nM wortmannin
Figure 5, supplement